Agios Pharmaceuticals, Inc. $AGIO Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 68.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 46,451 shares of the biopharmaceutical company’s stock after acquiring an additional 18,801 shares during the quarter. SG Americas Securities LLC’s holdings in Agios Pharmaceuticals were worth $1,264,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. NewEdge Advisors LLC acquired a new position in shares of Agios Pharmaceuticals during the first quarter worth $40,000. First Horizon Corp acquired a new position in shares of Agios Pharmaceuticals during the third quarter worth $45,000. Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals during the third quarter worth $79,000. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals in the first quarter valued at $133,000. Finally, North Star Asset Management Inc. purchased a new stake in Agios Pharmaceuticals in the third quarter valued at $201,000.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target on AGIO from $31 to $36 (keeps a “neutral” rating), signaling modest analyst support and giving the stock a near-term upside reference point for investors. JPMorgan price-target note
• Neutral Sentiment: Agios scheduled its Q1 2026 earnings conference call and webcast for April 29 — an upcoming catalyst that could drive volatility when results and guidance are released. Earnings call press release
• Neutral Sentiment: Multiple insiders (including CFO Cecilia Jones, and others such as Tsveta Milanova, Sarah Gheuens and James William Burns) sold small blocks (~2.9k–3.3k shares each) at about $34.71 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards — routine, planned transactions that are generally viewed as neutral rather than negative. Representative SEC filings and trade summaries are available for each insider. Sample SEC filing

Insiders Place Their Bets

In other news, insider Sarah Gheuens sold 2,940 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $102,047.40. Following the completion of the sale, the insider directly owned 80,277 shares of the company’s stock, valued at approximately $2,786,414.67. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Krishnan Viswanadhan sold 2,959 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares of the company’s stock, valued at $142,919.80. The trade was a 36.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 15,582 shares of company stock valued at $520,405. 4.30% of the stock is owned by insiders.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $35.11 on Wednesday. The firm has a fifty day moving average price of $29.13 and a 200 day moving average price of $32.10. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The stock has a market cap of $2.06 billion, a PE ratio of -4.94 and a beta of 0.79.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AGIO shares. Citigroup boosted their price target on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. The Goldman Sachs Group boosted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Finally, HC Wainwright boosted their price target on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $42.67.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.